medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2003, Number 4

<< Back Next >>

Ann Hepatol 2003; 2 (4)

Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report

Méndez-Sánchez N, Motola-Kuba D, Bahena-Aponte J, Chavez-Tapia N, Pichardo-Bahena R, Uribe M

Language: Spanish
References: 14
Page: 183-185
PDF size: 98.25 Kb.


Text Extraction

Nonalcoholic fatty liver disease (NAFLD) is a medical condition that may progress to end-stage liver disease. The spectrum of NAFLD is wide and ranges from simple fat accumulation in hepatocytes (steatosis), to fat accumulation plus necroinflammatory activity with or without fibrosis (steatohepatitis). In addition, NAFLD is the most common cause of abnormal liver-test results among adults with a prevalence of 13%-23%. This case report is an example of a patient with asymptomatic hypertransaminasemia and severe hepatic steatosis without inflammation in which the diagnosis was made by liver biopsy.


REFERENCES

  1. Ludwig J, Viggiano RT, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.

  2. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986; 8: 283-298.

  3. Angulo P. Nonalcoholic Fatty Liver Disease. N Engl J Med 2002; 346: 1221-1231.

  4. Reid AE. Nonalcoholic Steatohepatitis. Gastroenterology 2001; 121: 710-723.

  5. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The Utility of Radiological Imaging in Nonalcoholic Fatty Liver Disease. Gastroenterology 2002; 123: 745-750.

  6. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15: 539-543.

  7. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Valles V, Rios-Torres JM, Franco A, Olaiz G, Rull JA, Sepulveda J. Analysis of the agreement between the World Health Organization criteria and the National Cholesterol Education Program-III definition of the metabolic syndrome: results from a population-based survey. Diabetes Care 2003; 26: 1635.

  8. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001; 35: 195-199.

  9. Dixon JB, Bhathal PS, O´Brien PE. Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely Obese. Gastroenterology 2001; 121: 91-100.

  10. McNair A. Non-alcoholic steatohepatitis (NASH): Why biopsy? Gut 2002; 51: 898-899.

  11. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002; 50: 585-588.

  12. Sherwood P, Lyburn I, Brown S, Ryder S. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. BMJ 2001; 322: 276-278.

  13. Pratt DS, Kaplan MM. Evaluation of Abnormal Liver-Enzyme Results in Asymptomatic Patients. N Engl J Med 2000; 342: 1266-1271.

  14. Castańo G, Sookoian S. Hepatic focal fatty change in a chronic hepatitis C patient. Ann Hepatol 2002; 1: 147.




2020     |     www.medigraphic.com